CRUK Awards University of Birmingham £1.5M – Bowel Cancer Research
The Cancer Research UK has awarded researchers at the University of Birmingham £1.5 million to fund a five-year research programme aimed at finding new treatments for bowel cancer.
The pioneering research, the first of its kind in the UK, will see scientists taking samples of 200 patients’ bowel cancer in order to then grow avatars – or mini tumors – in the laboratory.
The avatars will then be exposed to over 2,000 drugs and treatments, some of which have never been previously tested.
Using genomic sequencing, scientists will also test the avatars to establish whether certain genes can make individuals predisposed to bowel cancer and whether these genes can be modified to reduce a person’s risk to the disease.
Dr Andrew Beggs, of the Institute of Cancer and Genomic Sciences at the University of Birmingham, said: “Bowel cancer is the fourth most common cancer in the UK and affects around 30,000 people a year, however only 60 to 70 percent of people survive so, therefore, there is a desperate need to develop new treatments and improve existing ones.
“By growing mini tumor models or avatars of bowel cancer, we can use them to test whether specific treatments work on bowel cancer with the hope that we can identify new treatments and ultimately save more lives. We also hope to gain a better understanding as to why some patient’s cancers are sensitive to radiotherapy and chemotherapy and, importantly, why others are not. This will help us better select patients who are likely to benefit from chemotherapy and radiotherapy.”
Dr. Karen Noble, head of research careers at Cancer Research UK, said: “We’re pleased to support the exciting work being done by Dr. Beggs and his team, in particular, their innovative approach to finding new treatments for bowel cancer.
“Clinical research is essential to find new and more effective ways to tackle cancer. Our Advanced Clinician Scientist Fellowship Award allows us to harness talented clinical minds to turn the most promising scientific discoveries into new treatments for patients.”
